Table 2.
Comparison of median antiretroviral therapy adherence rates at different time points for each group (N=40).
| ARTa adherence rate (%) measurement | Baseline, median (IQR) | 1-month visit, median (IQR) | 2-month visit, median (IQR) | P value | |
| Self-report | .22b | ||||
|
|
Control group | 100 (100-100) | 100 (100-100) | 100 (100-100) |
|
|
|
MISTc intervention group | 100 (100-100) | 100 (100-100) | 100 (100-100) |
|
| Pill count | .07d | ||||
|
|
Control group | N/Ae | 100 (100-100) | 100 (100-100) |
|
|
|
MIST intervention group | N/A | 100 (100-100) | 100 (100-100) |
|
| MEMSf | .63d | ||||
|
|
Control group | N/A | 100 (93-100) | 97 (93-100) |
|
|
|
MIST intervention group | N/A | 100 (93-100) | 97.5 (92-100) |
|
| MIST | |||||
|
|
MIST intervention group | N/A | 96 (87-100) | 94 (87-99) | .25d |
aART: antiretroviral therapy.
bFriedman test.
cMIST: Mobile Interactive Supervised Therapy.
dWilcoxon signed-rank test.
eN/A: Not applicable.
fMEMS: Medication Event Monitoring System.